180 Life Sciences Corp. (NASDAQ:ATNFW) Sees Large Drop in Short Interest

180 Life Sciences Corp. (NASDAQ:ATNFWGet Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 9,000 shares, a decline of 74.9% from the March 31st total of 35,900 shares. Based on an average daily volume of 46,100 shares, the days-to-cover ratio is currently 0.2 days.

180 Life Sciences Price Performance

ATNFW stock remained flat at $0.01 during midday trading on Thursday. The company’s stock had a trading volume of 3,172 shares, compared to its average volume of 47,164. 180 Life Sciences has a 1-year low of $0.00 and a 1-year high of $0.02. The business has a 50 day moving average price of $0.01 and a 200 day moving average price of $0.01.

About 180 Life Sciences

(Get Free Report)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

Further Reading

Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.